ARGA Investment Management LP Acquires Shares of 154,539 Zimmer Biomet Holdings, Inc. $ZBH

ARGA Investment Management LP acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 154,539 shares of the medical equipment provider’s stock, valued at approximately $15,222,000. ARGA Investment Management LP owned approximately 0.08% of Zimmer Biomet as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ZBH. Cary Street Partners Investment Advisory LLC raised its position in shares of Zimmer Biomet by 83.7% during the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 149 shares during the last quarter. Root Financial Partners LLC acquired a new stake in Zimmer Biomet in the 3rd quarter valued at $31,000. Mather Group LLC. bought a new stake in shares of Zimmer Biomet in the 3rd quarter worth about $36,000. Headlands Technologies LLC bought a new stake in Zimmer Biomet during the second quarter worth about $37,000. Finally, CoreFirst Bank & Trust bought a new stake in Zimmer Biomet during the 2nd quarter worth approximately $38,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. The Goldman Sachs Group lowered Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective on the stock. in a research report on Friday, January 9th. BTIG Research reaffirmed a “buy” rating and issued a $112.00 target price on shares of Zimmer Biomet in a research note on Thursday, January 8th. Royal Bank Of Canada dropped their price target on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, November 6th. UBS Group cut their price objective on shares of Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating on the stock in a research report on Thursday, November 6th. Finally, Johnson Rice set a $112.00 price target on Zimmer Biomet in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $107.33.

Zimmer Biomet Stock Down 1.1%

Shares of NYSE ZBH opened at $86.55 on Friday. The firm has a market cap of $17.15 billion, a PE ratio of 21.42, a price-to-earnings-growth ratio of 2.23 and a beta of 0.62. The company has a 50 day simple moving average of $91.34 and a 200 day simple moving average of $96.23. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.43 and a quick ratio of 1.39. Zimmer Biomet Holdings, Inc. has a 1 year low of $85.33 and a 1 year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The business had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the previous year, the company posted $1.74 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Tuesday, December 30th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.76%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.